Diabetes Research and Clinical Practice
Volume 70, Issue 2 , Pages 110-118 , November 2005

Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus

  • Sora Ludwig

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Sudharshan Dharmalingam

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Sharon Erickson-Nesmith

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Song Ren

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Fuqin Zhu

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Guoping M. Ma

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • Ruozhi Zhao

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • ,
  • John W. Fenton II

      Affiliations

    • Wadsworth Center, New York State Department of Health, Albany, NY, USA
    • ,
  • Frederick A. Ofosu

      Affiliations

    • Department of Pathology, McMaster University and Canadian Blood Services, Hamilton, Ont., Canada
    • ,
  • Henk te Velthuis

      Affiliations

    • Department of Immunopathology, Sanquin at CLB, Amsterdam, Netherland
    • ,
  • Gerald van Mierlo

      Affiliations

    • Department of Immunopathology, Sanquin at CLB, Amsterdam, Netherland
    • ,
  • Garry X. Shen

      Affiliations

    • Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835-715 McDermot Ave., Winnipeg, Man., Canada R3E 3P4
    • Corresponding Author InformationCorresponding author. Tel.: +1 204 789 3816; fax: +1 204 789 3987.

Received 6 May 2004 ,Revised 17 November 2004 ,Accepted 4 March 2005.

References 

  1. Ginsberg HN, Tuck C. Diabetes and dyslipidemia. Heart Fail. Monit. 2001;2:14–20
  2. Calles-Escandon J, Garcia-Rubi E, Mirza S. Mortensen A: Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron. Artery Dis. 1999;10:23–30
  3. Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J. Am. Coll. Cardiol. 1996;27:560–566
  4. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 1993;36:1119–1125
  5. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler. Thromb. Vasc. Biol. 1997;17:1121–1127
  6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001;21:1712–1729
  7. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996;335:1001–1009
  9. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349–1357
  10. Collins R, Peto R, Armitage J. The MRC/BHF heart protection study: preliminary results. Int. J. Clin. Pract. 2002;56:53–56
  11. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection study Collaborative Group: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016
  12. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002;106:2888–2893
  13. Paniagua JA, Lopez-Miranda J, Escribano A, Berral FJ, Marin C, Bravo D, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes. 2002;51:2596–2603
  14. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(Suppl. 2):72–78
  15. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, et al. Similar effects of atorvastatin simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb. Haemost. 2001;85:47–51
  16. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb. Res. 2002;105:285–290
  17. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 1994;74:735–737
  18. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu. Rev. Biochem. 1988;57:915–956
  19. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb. Haemost. 1991;65:153–159
  20. Gouin-Thibault I, Dewar L, Craven S, Kulczycky M, Wun TC, Ofosu FA. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo. Br. J. Haematol. 1996;95:738–746
  21. Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids The Oxford Cholesterol Study Group. Eur. Heart J. 1997;18:235–241
  22. Koh KK, Son JW, Ahn JY, Choi YM, Jin DK, Park GS, et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron. Artery Dis. 2001;12:305–311
  23. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada Canadian Diabetes Association. CMAJ. 1998;159(Suppl. 8):1–29
  24. Ren S, Lee H, Hu L, Lu L, Shen GX. Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. J. Clin. Endocrinol. Metab. 2002;87:286–291
  25. Arnman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb. Res. 1994;76:487–499
  26. Yorimitsu K, Saito T, Toyozaki T, Ishide T, Ohnuma N, Inagaki Y. Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction. Heart Vessels. 1993;8:160–162
  27. Loskutoff DJ, Edgington TE. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1977;74:3903–3907
  28. Cockell KA, Ren S, Sun J, Angel A, Shen GX. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells. Thromb. Res. 1995;77:119–131
  29. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990;10:1067–1073
  30. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Thromb. 1991;11:1821–1829
  31. Ren S, Man R, Angel A, Shen GX. Oxidative modification enhances lipoprotein(a)-induced production of plasminogen activator inhibitor-1 in vascular endothelial cells. Atherosclerosis. 1997;128:1–10
  32. Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998;18:1140–1148
  33. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients A case-control study. The PLAT Group.. Arterioscler. Thromb. 1993;13:1412–1427
  34. Haslinger B, Kleemann R, Toet KH, Kooistra T. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 2003;63:2065–2074
  35. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248–2253
  36. Fenton JW, Shen GX. Statins as cellular antithrombotics. Haemostasis. 1999;29:166–169
  37. Siegbahn A. Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis. 2000;30(Suppl. 2):41–47
  38. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc. Res. 2002;53:313–325
  39. Kario K, Matsuo T, Hoshide S, Kobayashi H, Sakata T, Mizuno O, et al. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Blood Coagul. Fibrinolysis. 1999;10:269–276
  40. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003;101:4387–4392
  41. Duering C, Kosch A, Langer C, Thedieck S, Nowak-Gottl U. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke. Thromb. Haemost. 2004;92:707–712
  42. Morange PE, Bastelica D, Bonzi MF, Van Hoef B, Collen D, Juhan-Vague I, et al. Influence of t-pA and u-PA on adipose tissue development in a murine model of diet-induced obesity. Thromb. Haemost. 2002;87:306–310
  43. Saito M, Morishita E, Asakura H, Jokaji H, Uotani C, Kumabashiri I, et al. Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases. Rinsho Ketsueki. 1996;37:794–798
  44. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 1995;15:879–885
  45. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis. 2001;154:203–212
  46. Ferro D, Basili S, Alessandri C, Mantovani B, Cordova C, Violi F. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet. 1997;350:1222–1225
  47. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756–1759
  48. Koh KK, Son JW, Ahn JY, Kim DS, Han SH, Ahn TH, et al. Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. Am. J. Cardiol. 2003;91:1231–1234
  49. Dichtl W, Stiko A, Eriksson P, Goncalves I, Calara F, Banfi C, et al. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999;19:3025–3032
  50. Lane A, Cruickshank JK, Mitchell J, Henderson A, Humphries S, Green F. Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease. Atherosclerosis. 1992;94:43–50

PII: S0168-8227(05)00105-1

doi: 10.1016/j.diabres.2005.03.025

Diabetes Research and Clinical Practice
Volume 70, Issue 2 , Pages 110-118 , November 2005

Article Tools

* Image Usage & Resolution